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Global, regional, and national incidence, prevalence, and YLDs for 301 
acute and chronic diseases and injuries for 188 countries, 1990-2013: a 
systematic analysis for the Global Burden of Disease Study 2013 
GBD 2013 Disease and Injury Incidence and Prevalence Collaborators 
Introduction 
The Global Burden of Diseases, Injuries, and Risk Factors 2013 Study (GBD 2013) is the first of a series 
of annual updates for the GBD studies that began with estimates for 1990 and were most recently updated 
to the year 2010. The 2010 update (GBD 2010) systematically quantified prevalence of 1,160 sequelae of 
289 diseases and injuries across 21 regions.1 National estimates for 187 countries were also derived based 
on the global and regional statistical analysis.1 Years lived with disability (YLDs), equal to the sum of 
prevalence times the general public’s assessment of the severity of health loss, was extensively used to 
explore patterns over time, age, sex, and geography.1 Results for specific diseases and impairments have 
been extensively published.2–46  These results have drawn attention to the importance of disability from 
musculoskeletal disorders, mental and substance abuse disorders, and a variety of other non-
communicable diseases.1 In developing countries, conditions such as anaemia and neglected tropical 
diseases remained important contributors to health loss.18,43,47  More generally, the analysis highlighted the 
global transition towards a rapidly increasing volume of YLDs due to global population growth and 
aging, combined with little progress in reducing age-specific YLD rates.  
Given the ambitious goal of the GBD 2010, to synthesise the global evidence on the country-age-sex-year 
prevalence of all major conditions, a number of specific estimates have been critiqued. Specific data 
sources, modeling assumptions, and aspects of the general approach have been challenged and there is  
widespread recognition that more and higher quality data could improve the estimates.48–52  Disability 
weights that were used to calculate YLDs were based on surveys of the general public in five countries 
(Bangladesh, Indonesia, Peru, Tanzania, and the United States) and an open internet survey. The validity 
of disability weights has been questioned for selected states including hearing loss, vision loss, drug use, 
spinal cord lesion, intellectual disability, and musculoskeletal disorders.53,54 Some authors have 
questioned whether disability weights should be measuring health or the loss of well-being associated 
with health states.53,55 In addition, the YLD uncertainty intervals were large for a number of conditions 
because of scarce data, the need to statistically adjust for different case definitions, measurement 
methods, and wide uncertainty intervals for disability weights. Wide uncertainty intervals have limited the 
number of statistically significant differences for some conditions reported across time and countries. 
Broad interest and critical discourse on the GBD has also brought to light many unpublished data sources 
in specific countries that could be used to strengthen the analysis.  
Given the prominent role attached to quantification of disease burden for health research and policy 
nationally and globally, up-to-date estimates reflecting the latest evidence for descriptive epidemiology 
constitute an essential global public good.22–27,32,56–60  The GBD 2013 provides an opportunity to 
incorporate constructive critical commentary on GBD 2010 data sources, model development, methods, 
and interpretation. Additionally, the GBD 2013 reflects methodological advances and includes new data 
on disability weights, capturing many new published or unpublished data sources for the conditions 
included in the GBD. In this paper, we report on the data, methods, and results analysing 188 countries 
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for the period 1990 to 2013 for 301 diseases and injuries and their 2,337 sequelae. We report incidence 
for acute sequelae and prevalence for chronic sequelae in addition to YLDs for all causes. Because 
prevalence and YLDs for the entire period from 1990 to 2013 are re-analysed using consistent data and 
methods, these results supersede any prior publications on the GBD.  
Methods 
Overview 
Our general approach is similar to the GBD 2010. The analysis of incidence and prevalence for 
HIV/AIDS, tuberculosis (TB), and malaria for GBD 2013 have already been published in detail.61 Key 
changes from GBD 2010 are the inclusion of new data through updated systematic reviews and the 
contribution of unpublished data sources from many collaborators; elaboration of the sequelae list to 
include asymptomatic states, such as Plasmodium falciparum parasitemia (PfPR) without symptoms; 
utilisation of more detailed nature of injury codes (N-codes); improvements to the Bayesian meta-
regression method; increased simulation size for comorbidity; estimation of the prevalence of injuries by 
cohort; and use of a novel method to estimate the distribution of mild, moderate, and severe anaemia by 
aetiology.  
Cause and sequelae list changes 
Based on feedback from GBD 2010, as well as input from the GBD 2013 collaborators, we expanded the 
cause and sequelae list (Appendix Table A.1). There are several key changes. First, we have included 
asymptomatic states as explicit sequelae so that overall disease prevalence estimates are available, which 
may be useful for disease targeting, health service planning, or mass treatment strategies. Asymptomatic 
sequelae, by definition, are not associated with ill health and therefore are not assigned disability weights. 
Second, to deal with the challenge that some of the nature-of-injury categories used in the GBD 2010 
were highly heterogeneous, these categories has been expanded from 23 to 47. Third, we added a number 
of new causes and sequelae. All these additions to the cause list were based on either reducing the size of 
large residual categories, such as other injuries, or recognition of marked epidemiological heterogeneity 
within a disease category (Appendix Table A.1). With these changes, the cause list has expanded from 
289 to 301 causes and from 1,160 to 2,337 sequelae. The majority of the increase in sequelae is due to the 
expansion of the nature-of-injury sequelae which apply to each of the external causes of injuries. 
Appendix Table A.2 provides a list of ICD-10 and ICD-9 codes for all GBD causes and the nature-of-
injury categories. 
Identification, documentation, and representativeness of data sources 
GBD 2010 collaborators undertook systematic reviews for the majority of causes and sequelae. For some 
sequelae the vast majority of data came from household survey micro-data re-analysis and administrative 
data such as hospital discharges. For others, the majority of data was extracted from published literature. 
Documentation of the GBD 2010 systematic reviews, however, was not centralised and only some of 
these reviews have been published. For this study, we updated systematic reviews through August 2013. 
In some cases, studies published after August 2013 have been identified and included based on GBD 
collaborator input; no data or studies were extracted after November 2014. Household surveys including 
the Demographic and Health Surveys, Multiple Indicator Cluster Surveys, Living Standards Measurement 
Surveys, Reproductive Health Surveys, and various national health surveys included in the Global Health 
Data Exchange (ghdx.healthdata.org) were systematically screened for data relevant to sequelae. For 
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some diseases, case notifications reported to the World Health Organization (WHO) have been used as 
inputs and have been updated through 2013. Appendix Table A.3 provides a full list of citations for 
sources organised by country used for this analysis.  
We have computed an index of the geographic and temporal representativeness of the data sources 
available on non-fatal health outcomes for each cause or impairment – the data representativeness index 
(DRI). The overall DRI simply counts what fraction of countries have any incidence, prevalence, 
remission, or excess mortality data available for causes that are prevalent in that country. We do not count 
cause of death data in this measure, even if it is used in the estimation of incidence or prevalence. We 
compute the same measure for three time periods: prior to 1998, 1998 to 2005, and 2006 onwards. Table 
1 provides the overall DRI and period-specific DRI measures for each cause and Table 2 provides the 
same information for estimation of total impairment prevalence. The DRI has also been computed for 
Level 1 and Level 2 causes (aggregate causes) by counting data availability for any cause within that 
aggregate. This metric simply reflects availability of data and does not incorporate any assessment of data 
quality. The all-cause DRI is 100% overall and for each time period, indicating that there is at least data 
on one cause for all 188 countries in each time period. At more detailed levels, however, there is wide 
variation in the DRI across causes and time. DRI ranges from below 2% for 8 causes, including G6PD 
trait and other mental and substance abuse disorders, to 100% for Chagas, African trypanosomiasis, and 
food-bourne trematodiases. Causes with required infectious disease case reporting have high DRI values. 
Other conditions, such as cancers, have DRI values above 70% due to the network of population-based 
cancer registries. While the time trend varies by condition, many of the highest DRI values are from 1998 
to 2005. The lag in data analyses and publications may explain lower DRI values for the period of 2006 to 
present.  
Data representativeness can also be examined at the country level. Figure 1 shows a map of the percent of 
causes for which there is data available in each of the 188 countries between 1990 and 2013. The DRI 
values range from 6% in South Sudan to 92% in the USA. Many developed countries have data for more 
than 65% of causes; Brazil, India, and China have similar levels. Low levels of data availability are seen 
in a number of sub-Saharan African countries, Central Asia, the Caribbean, and the Balkans. Within 
regions there is marked variation; for example Kenya has 49%, while Djibouti has less than 10%; Laos 
has 14%, and Thailand has 54%.  
Estimating sequelae incidence and prevalence 
Appendix Table A.4 provides a brief description of the modeling strategy used for each sequela and 
cause. The most extensively used estimation method is the Bayesian meta-regression method DisMod-
MR 2.0. For some causes such as HIV or hepatitis B and C, disease-specific natural history models have 
been used where the underlying three state model in DisMod-MR 2.0 (susceptible, cases, dead) is 
insufficient to capture the complexity of a disease process. For some diseases with a range of sequelae 
differentiated by severity, such as chronic obstructive pulmonary disease (COPD) or diabetes mellitus, 
DisMod-MR 2.0 is used to meta-analyse the data on overall prevalence. Separate DisMod-MR 2.0 models 
are then used to analyse data on the proportion of cases with different severity levels or sequelae. 
Likewise, DisMod-MR 2.0 is used to meta-analyse data on the proportions of liver cancer and cirrhosis 
due to underlying aetiologies such as hepatitis B, hepatitis C, and alcohol use. For acute sequelae, we 
report incidence (defined by a duration of three months or less) at the cause level in Table 3, as incidence 
is the preferred measure for conditions of short duration. 
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DisMod-MR 2.0 represents a major advance in the computational speed, geographic disaggregation of 
full internally consistent posterior estimation, and display of data results as compared to DisMod-MR 1.0, 
which was used in GBD 2010. Through cross-validation tests, Flaxman et al. found that the log rates 
specification of models worked as well or better than the negative binomial specification used in DisMod-
MR 1.0.62 Based on these findings, as well as the substantial improvements in computational speed for 
log rate models, this specification is the default method for DisMod-MR 2.0. Appendix B provides details 
of the DisMod-MR 2.0 likelihood estimation. The source code for DisMod-MR 2.0 is available at 
http://ihmeuw.org/dismod-ode. The DisMod-MR 1.0 sequence of global estimation, regional estimation, 
and country prediction, which we call an analytical cascade, is illustrated in Appendix Figure B.1. 
Dismod-MR 2.0 uses a more complete cascade (Appendix Figure B.2). At the global level, a mixed 
effects non-linear regression using all available country data is used to generate super-region priors. In 
turn, a super-region specific mixed effects non-linear regression is used to estimate for regions. The same 
regression method is used for estimating further geographic disaggregation. The analyst can choose, 
depending on data density, to branch the cascade in terms of time and sex at different levels. In GBD 
2010, DisMod-MR 1.0 was used to generate fits for three time periods only: 1990, 2005, and 2010 
because of long computational time. For GBD 2013, we generate fits for 1990, 1995, 2000, 2005, 2010, 
and 2013.  
DisMod-MR 2.0 internal validity was assessed using R-Squared for adjusted data. Results for all 
DisMod-MR 2.0 models are provided in Appendix Table B.1. Adjusted data are the original study data 
transformed to the reference case definition and measurement method, using the meta-regression 
component of DisMod-MR 2.0 to make the data from different studies with varying methods comparable. 
External validity was also evaluated by performing cross-validation on a limited number of sequelae due 
to the computational time and complexity for this analysis. We selected 10 DisMod-MR 2.0 models 
representing a range of data densities to evaluate. We held out 30% of data points for incidence and 
prevalence at random, refit the model, and compared predictions to the held-out data. We assessed model 
performance using two metrics: the root-mean squared error (RMSE) of the predictions compared to the 
data held-out, and the coverage of the data prediction with 95% uncertainty intervals. Appendix Table B.2 
provides these metrics for the 10 models tested. In all cases, external validity was equal to or only slightly 
worse than internal validity.  
As in GBD 2010, DisMod-MR was not used to model estimates for a short list of causes; custom models 
were created for many of these. For some of these causes, important improvements in the modeling 
strategy have been implemented. Changes for HIV and malaria have been described elsewhere.61 For 
dengue, the model was modified to use the first component of a principal components analysis of Bhatt et 
al.’s dengue transmission probability in order to improve estimation of case rates.63 For lymphatic 
filariasis (LF), pre-control levels were estimated from data reported in the LF Atlas.64 Finally, based on 
critical input from GBD collaborators, we chose to model rheumatic heart disease (RHD) in low- and 
middle- income countries separately from high-income countries given potential differences in long-term 
cohort effects of treatment.  
Estimation for cancer in GBD 2013 largely followed a similar analytical strategy to GBD 2010, which 
used a combination of incidence data, survival data, and sequelae durations to estimate cancer prevalence 
and YLDs.65,66 The analysis benefited from the inclusion of both the latest edition of Cancer Incidence in 
Five Continents (Ci5) and a larger number of other cancer registries particularly in China. In GBD 2013, 
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we also incorporated new data from the National Cancer Institute’s Surveillance, Epidemiology, and End 
Results Program (SEER) and the World Health Organization’s International Agency for Research on 
Cancer’s (IARC) Cancer Survival in Africa, Asia, the Caribbean, and Central America (SurvCan) to 
update best and worst case survival, yearly survival trends, and sequelae durations for all cancers.67,68 
Based on evidence that individuals with most cancers continue to have excess mortality beyond five years 
as compared to the general population, we now estimate the burden of cancer to ten years after incidence. 
Estimates for cancer  sequelae now represents the burden for all cancer patients in contrast to estimating 
burden just for cancer survivors (see Appendix C for greater detail on aspects of estimating non-fatal 
cancer outcomes that were different from the methods used in GBD 2010). 
Injuries Analysis 
We followed a similar strategy to GBD 2010 for estimating the burden of injuries but for an expanded list 
of 26 external cause-of-injury categories (from 15) and 47 nature-of-injury categories (from 23) for both 
short-term outcomes and lasting disability (see Appendix Table A.2 for ICD codes). More detail was 
added to both external causes and nature of injury categories to reduce epidemiological heterogeneity 
within each combination of cause and nature-of-injury category. The key analytical steps are explained in 
greater detail in Appendix D. Here we provide a summary of the methods. 
First, for each external cause, DisMod-MR 2.0 was used to analyse incidence based on hospital, 
emergency department, and survey data. Second, we estimated the distribution of nature of injury for each 
external cause using data that has been dual E- and N-coded where available. Where individuals were 
coded with more than one N-code, we used the most severe. Third, we analysed seven studies that 
provided at least one year follow-up for various natures of injury to estimate long-term disability.69–75 
Fourth, we estimated cohort prevalence of long-term disability from the incident cases of injury for each 
E-N combination while accounting for excess mortality for the more severe post-injury sequelae. For 
some injuries, treatment modifies the disability weight. In these cases, we approximated the fraction of 
injuries receiving treatment as a function of an indicator of health system access.76  
Short-term disability was estimated for all nature-of-injury by cause-of-injury categories as the product of 
prevalence (estimated by multiplying incidence by average duration) and the appropriate disability 
weight. The duration for treated cases of injuries was determined in the Dutch Injury Surveillance System 
follow-up studies of 2007-2010 and 2001-2004.71,73 We used expert opinion to estimate a multiplier for 
the duration of short-term disability from untreated injuries and used the estimates of access to care by 
country and year as we describe for the long-term disability. 
YLDs from 29 residual causes 
Despite expanding our list of causes and sequelae in GBD 2013, many diseases remain for which we do 
not explicitly model disease prevalence and YLDs. The GBD cause list is collectively exhaustive such 
that all sequelae with an ICD code are mapped to a cause group (Appendix Table A.2). Many less 
common sequelae are included in 29 of the residual categories. For 14 of these cause groupings, 
epidemiological data on incidence or prevalence are available so that they can be modeled as other causes 
have been modeled – this set includes meningitis, cirrhosis, liver cancer, pneumoconiosis, and chronic 
kidney disease due to other causes; other neoplasms; other cardiovascular and circulatory diseases; other 
drug use disorders; other mental and substance use disorders; other gynecological diseases; other 
musculoskeletal disorders; other skin and subcutaneous diseases; age-related and other hearing loss; age-
related and other vision loss; other sense organ diseases; and other oral disorders. For 12 residual 
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categories (other intestinal infectious diseases, other neglected tropical diseases, other maternal disorders, 
other neonatal disorders, other nutritional deficiencies, other infectious diseases, other chronic respiratory 
diseases, other digestive diseases, other neurological disorders, other urinary diseases, other 
hemoglobinopathies and hemolytic anaemias, and other congenital anomalies), epidemiological data on 
incidence and prevalence were not available for the entire residual cause grouping but sufficient cause of 
death data allowed for cause of death estimates. For these categories, we estimate YLDs by scaling the 
YLD age-sex pattern for other diseases in the same Level 2 category by the ratio of YLLs from the 
residual category to the YLLs from the other diseases, this scaling is undertaken for each country-sex-
year.  This approach makes the simplifying assumption that on average within a Level 2 disease grouping 
the experience of disability is proportionate to mortality within a country-sex-year. For an additional three 
residual categories (other sexually transmitted diseases, other drug use disorders, and other mental and 
substance use disorders), there were no overall epidemiological data nor sufficient deaths to generate 
cause of death estimates. For the latter two, we used USA outpatient data or prevalence data from MEPS, 
NESARC, or the 1997 Australian mental health survey and apply a severity distribution from these 
surveys in all countries and time periods. These two causes for which USA and Australian data are 
applied worldwide account for 1.6% of global YLDs.  
Impairments 
As in GBD 2010, we estimated the country-age-sex-year prevalence of nine impairments: anaemia, 
epilepsy, hearing loss, heart failure, intellectual disability, infertility, vision loss, Guillain-Barré 
syndrome, and pelvic inflammatory disease. These were selected because these impairments are sequelae 
of multiple diseases and data are available to estimate prevalence for the overall impairment. In general, 
overall impairment prevalence was estimated using DisMod-MR 2.0. Cause-specific estimates of 
impairments, such as the 19 causes of blindness, are required to sum to the total prevalence estimated for 
that impairment. Anaemia, epilepsy, hearing loss, heart failure, intellectual disability, and pelvic 
inflammatory disease are estimated for different levels of severity. Separate estimates were made for 
primary infertility (in couples who have not been able to conceive) and secondary infertility (in couples 
having trouble conceiving again) and, for each, if the impairment is affecting men and/or women. The 
severity distribution of cause-specific prevalence of each impairment was either estimated as explained 
above or, in the absence of severity-specific data, assumed to be proportionate across all levels of 
severity. In the case of epilepsy, severity levels were determined by DisMod-MR 2.0 proportion models 
for primary, severe, and treated epilepsy, and a meta-analysis for seizure-free treated epilepsy, and thus 
had values that were specific for country, age, sex, and year. Similarly, DisMod-MR 2.0 models produced 
country-, age-, sex-, and year- specific levels of hearing loss and vision loss. Due to limited information 
on the severity levels of intellectual disability, we assumed a similar distribution of severity globally 
based on meta-analysis of IQ-specific data for the overall impairment. This was supplemented by 
aetiology-specific distributions for chromosomal causes and iodine deficiency, while the severity of 
intellectual disability included in the long-term sequelae of causes such as meningitis, neonatal tetanus, 
and malaria was combined with multiple impairments such as motor impairment, blindness, and/or 
seizures. The severity of heart failure is derived from our MEPS analysis and therefore is not specific for 
country, year, age, or sex. 
Our method for estimating overall anaemia was largely the same as in GBD 2010 but with the addition of 
new data sources, especially sub-national data for the United Kingdom, China, and Mexico.43 We adopted 
different thresholds for defining anaemia during the neonatal period, as the GBD 2010 thresholds did not 
7 
 
account for hematologic realities of early life. The GBD 2013 thresholds match the WHO 
recommendations77 with the exception of thresholds for those under one month, as there is no 
international cutoff for diagnosis at that age.43,78 In order to disaggregate marginal estimates of anaemia 
severity and aetiology into a complete set of prevalence estimates for aetiology/severity pairs, we 
developed a new method for GBD 2013 that employed techniques from Bayesian contingency table 
modeling.79,80  
In GBD 2010, hearing loss of more than 35+ db in DisMod-MR 1.0 was estimated and then broken down 
into six severity levels based on a series of regressions on the proportionate distribution across categories. 
In GBD 2013, we first estimated the prevalence of normal hearing, hearing loss of 20-34 dB (mild), and 
greater than 35 dB (moderate and above); these three categories were constrained to add up to 100%. We 
then ran separate DisMod-MR 2.0 models for five severity levels (i.e., moderate 35-49, moderately severe 
50-64, severe 65-79, profound 80-94, and complete 95+ dB), which were then proportionally rescaled to 
fit in the 35+ dB envelope. In GBD 2010, the same severity distribution was assumed for each cause of 
hearing loss. In GBD 2013, we customised the prevalence estimation for each aetiology. Hearing loss due 
to otitis media and age-related hearing loss were estimated by DisMod-MR 2.0 using prevalence data. 
Hearing loss due to meningitis was estimated as a proportion of meningitis cases from a meta-analysis.81 
Congenital hearing loss was estimated using birth prevalence data in DisMod-MR 2.0, assuming a 
constant prevalence throughout all ages, as no evidence was found to support an increased mortality risk. 
We assumed all hearing loss from otitis media is mild or moderate based on reported distribution of 
hearing loss.82,83 To account for hearing aids, we assume the use of a hearing aid reduces the severity of 
hearing loss by one level. The other aetiologies were assumed to cover the full range of severities. More 
details on impairments are provided in the Appendix E. 
 
Severity distributions 
For 190 causes, a range of sequelae are defined in terms of severity. Important changes to the sequelae list 
with regards to severity include low back pain, alcohol and drug dependence categories, uterine prolapse, 
and epilepsy. Milder states for low back pain and alcohol and drug dependence categories were added, as 
these conditions had a large gap between asymptomatic cases and the high value of the disability weight 
for the least severe symptomatic categories while the epidemiological data on severity indicates a sizeable 
proportion of cases with milder disability. Stress incontinence was added as a sequela of uterine prolapse 
with a new disability weight that is distinct from full incontinence. Lastly, epilepsy health states are now 
better aligned with epidemiological data based on seizure frequency. In cases where severity is related to 
a particular impairment, such as mild, moderate, and severe anaemia due to malaria, the analysis is driven 
by the impairment estimation described below. For some outcomes such as COPD or asthma, data have 
been collected in different locations around the world and these have been modeled using DisMod-MR 
2.0 (see Appendix Table A.4 for details). In other cases, published meta-analyses have been used to 
estimate the allocation of cases by severity level. For the remaining causes, we used the same approach 
for estimating the distribution of severity as in the GBD 2010; empirical analysis of this model was 
updated through the addition of two more years from the US Medical Expenditure Panel Survey (MEPS). 
Appendix Table A.5 lists the GBD causes that can be identified in MEPS and the corresponding ICD-9 
CM codes.  In total, 203,960 observations were used covering 119,676 individuals. In the cases of 
dementia, Parkinson’s disease, multiple sclerosis, osteoarthritis, schizophrenia, and bipolar disorder, data 
identified through literature reviews was used to inform the severity distribution. The introduction of a 
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health state for mild drug dependence required identification of epidemiological data to estimate the 
proportion of cases with mild versus more severe disability. For cannabis dependence, we used the 
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) survey in the USA and 
the Australian National Survey of Mental Health and Wellbeing. For the remaining three drug 
dependence categories, we only had access to one study on poly-drug users in Australia, which led to 
about half of dependent cases being assigned to the more severe and mild health states. While this 
information is derived from a non-representative cohort of drug users, it was considered more appropriate 
than deriving a severity distribution from a household survey like NESARC in which only a small 
proportion of those dependent on opioids, cocaine, or amphetamines would be represented.  
Revisions to disability weights 
The GBD 2010 Disability Weights Measurement study introduced a new method of pairwise comparisons 
as a means of eliciting weightings for health states in population surveys.84,85 Data were collected in five 
countries (Bangladesh, Indonesia, Peru, Tanzania, and the United States) and supplemented with a web 
survey. In total, responses were collected from 30,230 people in 167 countries. Respondents were 
presented with a series of randomly selected pairwise comparisons of lay descriptions of health states and 
asked to state which health state is healthier than the other. Salomon et al. developed a statistical model 
that yields from these pairwise comparisons disability weights on a scale from 0 (no health loss) to 1 
(equivalent to death).84 Based on critical commentary and review of the GBD 2013 collaborators, we have 
revised the lay descriptions of 32 states and added 16 new states. The revised lay descriptions were based 
on identifying inconsistency in the way progression across levels of severity had been handled for some 
outcomes and the addition of social isolation to the descriptions for complete, profound and severe 
hearing loss. New states included five milder health states for alcohol and drug dependence; two health 
states for epilepsy aligning with the epidemiological data defining severe epilepsy in persons who 
experience on average one or more fits a month and less severe epilepsy in those with between one and 
eleven fits in the past year; two milder health states for low back pain; and one each for stress 
incontinence, concussion, hypothyroidism, hyperthyroidism, thrombocytopenic purpura, vertigo, and 
amputation of one arm without treatment). Appendix Table A.6 provides a complete listing of the lay 
descriptions of all 235 GBD 2013 health states.  
In 2013, we had the opportunity to collaborate with the European Centre for Disease Prevention and 
Control to collect new data on disability weights in four population-based national surveys (Hungary, 
Italy, Sweden, and the Netherlands) using the Salomon et al. protocol.84,86 For reasons of funding and 
instrument length, the surveys included 140 of the 220 GBD 2010 health states for which the lay 
descriptions had not been revised, 32 health states with revised lay descriptions, and 42 new health states, 
16 of which were included in GBD 2013. These nationally representative samples were comprised of 
30,660 respondents. For GBD 2013, the data of GBD 2010 Disability Weights Measurement study and 
the European Disability Weights Measurement study were pooled in a single analysis of individual 
responses, thus more than doubling the number of respondents to 60,890 in both studies. For states where 
the lay description was not previously included, revised, or new, only the European Disability Weights 
Measurement study data were used. This means that all disability weights in GBD 2013 differ from the 
GBD 2010 disability weights. Most disability weights have changed only marginally, but some differ 
more widely (Appendix Table A.7). Some of the more substantial changes were due to the inclusion of 
incontinence to the lay descriptions for spinal cord injury and the inclusion of the psychological 
consequences of social isolation in people with more severe hearing loss which led to much higher 
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disability weights. The statistical analysis generates uncertainty distributions for each disability weight 
which are propagated into the uncertainty distributions of the estimates of YLDs.  
Comorbidity 
Disability is experienced by individuals; many individuals experience more than one disease or injury 
sequela at the same time. To accurately, account for comorbidity and its impact on disability for 
individuals, we used the GBD 2010 micro-simulation approach. In the micro-simulations, a set of 
individuals are exposed to the probability of having all the different sequelae included in the GBD to 
estimate a distribution of the combinations that might be observed in each country-age-sex-year. We 
model the probabilities within each country-age-sex-year of different sequelae as independent. While 
there are clear examples where the probability of one sequela changes the probability of other sequelae, 
such as diabetes and ischemic heart disease, testing reported in Vos et al. suggested that modeling 
assuming independence was a reasonable approximation.1 However, for less common sequelae the micro-
simulation tends to increase the estimated uncertainty in the number of YLDs substantially; because for 
example a sequela that is estimated to have a prevalence of less than 1 in 10,000 will not at random 
appear in many micro-simulations of size 20,000. Two steps have been taken to reduce the inflation of 
uncertainty for uncommon sequelae. First, the number of simulants in each country-age-sex-year was 
increased to 40,000; the main limiting factor for the number of simulants is computational resources 
required to run 62,880 country-age-sex-year simulations each 1000 times to account for uncertainty in 
each of the input prevalence rates. Second, for sequelae in a country-age-sex-year with a prevalence less 
than 1 in 20,000, we exclude these from the micro-simulation. YLDs for these sequelae, however, were 
corrected by the average reduction in YLDs a country-age-sex-year of sequelae included in the micro-
simulation compared to a simple calculation of prevalence multiplied by disability weight. The combined 
disability weight for individuals with multiple sequelae was computed as in the GBD 2010 using a 
multiplicative model; namely, the individuals’ disability weight is equal to one minus the cross product of 
one minus the disability weight for each sequela that the individual experiences. An output from the 
comorbidity micro-simulation is counts of the number of sequelae for each simulant in the population. 
The numbers of simulants with different comorbidities in a country-age-sex-year was adjusted from 
40,000 to equal the estimated population in each age-sex-country-year to produce the estimated 
distribution of individuals in each country with comorbidities. Sequelae with a prevalence of less than one 
in 20,000 that were not included in the micro-simulation, are also not included in the population pyramids 
showing individuals by numbers of sequelae (Figures 2a-c). A technical description of the comorbidity 
simulation is given in Appendix A. 
Uncertainty intervals 
We report 95% uncertainty intervals for each quantity in this analysis. For disease or sequelae incidence 
or prevalence rates, age-standardised rates or counts, the models such as DisMod-MR 2.0 provide 
posterior distributions of each quantity from which 95% uncertainty intervals are computed. For YLDs, 
we incorporate uncertainty in prevalence and uncertainty in the disability weight into the posterior 
distribution of YLDs. In practice, we estimate the posterior distribution of YLDs by taking 1000 samples 
from the posterior distribution of prevalence and 1000 samples of the disability weight to generate 1000 
samples of the YLD distribution. We estimate the 95% uncertainty interval by reporting the 25th and 975th 
values of the distribution. Uncertainty intervals for YLDs at different points in time (1990, 1995, 2000, 
2005, 2010, and 2013) for a given disease or sequelae are correlated because of the shared uncertainty in 
the disability weight.  
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Results 
We begin the presentation of results with population pyramids illustrating number of sequelae, followed 
by global estimates of the incidence of acute conditions, the prevalence of chronic diseases, and then 
common impairments such as vision loss, hearing loss, and anemia. We then present the changes in YLDs 
between 1990 and 2013 globally and by country, decomposing these trends into underlying causes. 
 
Population distribution by number of sequelae 
Figures 2a, 2b, and 2c show the population pyramid for developed countries, developing countries 
excluding sub-Saharan Africa, and sub-Saharan Africa in 1990 and 2013 broken down by the number of 
sequelae, ranging from very mild to severe, experienced by each individual. The vast majority of the 
world's population suffers from at least one of the GBD sequelae and most people have multiple. As 
expected, given the strong relationship between age and disease prevalence for most non-communicable 
diseases (NCDs) and injuries, the number of individuals with multiple morbidities rapidly increases with 
age. In developed countries, 35.9% of the age-group 0-4 has no sequela with only 0.03% over age 80 with 
no sequela. In the age-group over 80, 10.3% have 1-4 sequelae, 64.6% 5-9 sequelae and 25.1% have 10 or 
more sequelae. The percent of each age-group with multiple morbidities rises progressively with age 
regardless of the cutoff used to define multiple morbidities. Due to this relationship and the demographic 
shifts towards older ages in developed countries, the number with more than 10 sequelae increased by 
51.6% from 1990 to 2013. In the oldest age-group, 23.6% of women have more than 10 sequelae and 
27.8% of men but the large population imbalance at older age favoring women means that there are 1.4 
times more women with 10 or more sequelae compared to men.  
Figure 2b shows the pyramids for developing countries outside of sub-Saharan Africa and documents that 
the birth cohorts today are smaller than in 1990. The major demographic change is the large expansion of 
adults in the age groups 20 to 54 for men and women. Comparing 1990 and 2013, there is little change in 
the distribution of the population in each age-group by number of sequelae. Rising numbers with multiple 
morbidities are driven by aging. 20.3% of the age-group 0-4 has no sequela and 0.05% over age 80. In the 
oldest age group, 12.5% have 1-4 sequelae, 63.9% have 5-9 sequelae, and 23.5% have 10 or more 
sequelae.  
As shown in Figure 2c the dominant result is the massive growth in population from 1990 to 2013 and 
continued pattern of a population with a low percent of the population at older ages driven by high 
fertility and comparatively high mortality. Due to a number of very common sequelae that start early in 
life such as anaemia, soil-transmitted helminths, and schistosomiasis, only 7.8% of the age-group 0-4 in 
sub-Saharan Africa have no sequelae; by age 80 this is 0.002%. Although there are comparatively few 
individuals reaching the oldest age-groups, in the population 80 and over, 1.9% have 1-4 sequelae, 42.6% 
have 5-9, and 55.5% have 10 or more sequelae which is higher than in developed countries. Multiple 
morbidities are also common in all regions in working age adults: 31.7% with 5 or more sequelae in 
developed, 37.9% in developing outside of SSA, and 61.6% in sub-Saharan Africa. Of the 2.3 billion 
individuals in 2013 with more than 5 sequelae, 81.4% of them are under age 65.  
Global incidence of acute conditions 
The comprehensive and systematic nature of the GBD provides an opportunity to examine the most 
common acute conditions affecting people around the world and their trends from 1990 to 2013. Table 3 
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shows the 65 causes of acute (less than 3 months duration) disease and injury incidence with more than 1 
million cases per year in 2013. For the causes with more than one acute sequela, such as typhoid fever 
(acute infection, intestinal perforation and intestinal bleeding), maternal sepsis (puerperal sepsis and other 
maternal infections), or hypertension in pregnancy (eclampsia, pre-eclampsia and other hypertensive 
disorders in pregnancy), we aggregate all the acute sequelae for a cause for presentation in this table. Of 
note, there are two conditions with incidence in 2013 greater than 1 billion: upper respiratory infections 
(18.8 billion) and diarrheal diseases (2.7 billion). Another twelve diseases and injuries cause from 
between 100 million to 1 billion incident cases a year: injuries due to other exposure to mechanical force; 
acute otitis media; tooth pain due to caries of permanent teeth; pyoderma (including impetigo and 
abscess); falls; lower respiratory infections; clinical episodes of malaria, chlamydia infection; varicella 
(including chickenpox and herpes zoster episodes); acute hepatitis B; gallbladder and biliary tract disease; 
and acute hepatitis A. There are 28 diseases and injuries with incident cases between 10 million and 100 
million per year including a number of injuries; such as non-venomous animal contact, motor vehicle road 
injuries, fire, heat and hot substances, motorcycle and pedestrian injuries, and infections such as urinary 
tract infections, typhoid, hepatitis C and E; dengue; gonorrhea; the initial episodes of genital herpes, 
trichomoniasis; as well as a number of conditions affecting the digestive system, including gastritis and 
duodenitis, peptic ulcer disease, pancreatitis, and appendicitis.  
Among the most common causes of acute disease incidence, 47 are increasing in absolute numbers of 
incident cases but only 13 have rising age-standardised rates of which six have statistically significant 
increases (upper respiratory infections, interstitial nephritis and urinary tract infections, dengue, 
pancreatitis, paralytic ileus and intestinal obstruction, and unintentional suffocation). Declining numbers 
are limited to 18 of 65 causes in the table, seven of which are infectious diseases that dominantly affect 
children. Two are maternal disorders and for one, peptic ulcer disease, the decline is not significant. Some 
injuries such as non-venomous animal contact, fire, heat and hot substances, collective violence and legal 
intervention, exposure to forces of nature, venomous animal contact, poisoning, and drowning are 
declining in absolute incidence numbers. For 52 of 65 causes, age-standardised rates are in fact declining, 
meaning that for 34 causes, numbers are increasing due to demographic change even though age-
standardised rates are declining. In the set of causes causing more than 1 million cases per year, dengue 
has experienced the most dramatic increase in the age-standardised rates (447.3%).  
Global prevalence of chronic diseases 
Table 4 summarises the prevalence of chronic disease and injury sequelae (duration of greater than 3 
months) aggregated to the cause level. This table provides a high-level view of the leading causes 
globally of chronic conditions for the 59 causes with a global prevalence greater than 1% in 2013 – note 
overall prevalence of impairments such as vision or hearing loss are presented in Table 6. Leading causes 
are a mixture of oral conditions, neurological conditions, skin diseases, musculoskeletal disorders, 
neglected tropical diseases, gynecological disorders, chronic kidney disease, some causes of anaemia, 
age-related hearing, other vision loss and injuries. Eight causes affect more than 10% of the world 
population in 2013: permanent caries without pain, tension-type headaches, iron-deficiency anaemia, 
G6PD trait, age-related and other hearing loss, genital herpes without symptoms, migraine, and ascariasis. 
Another 51 causes afflict between 1% and 10% of the world’s population. Among this set of conditions 
are a number that are not prominent causes of YLDs because the average disability weight is 
comparatively low, but may be important in terms of health system resources or health service planning. 
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These include G6PD deficiency, genital prolapse, premenstrual syndrome, edentulism, polycystic ovary 
syndrome, uterine fibroids, and a number of skin diseases.  
Rates for only six causes of chronic disease (Table 4) are declining fast enough to lead to declines in the 
absolute numbers in the world with each condition; these are comprised of micro-nutrient deficiencies, 
worm infestations, and acute hepatitis B. As noted in Table 3, a number of acute infectious diseases and 
other acute conditions are also declining in absolute numbers. A further 17 chronic conditions have 
increasing numbers of cases but statistically significant declines in age-standardised rates: age-related and 
other hearing loss, genital herpes, uncorrected refractive error, deciduous caries without pain, dermatitis, 
edentulism and severe tooth loss, osteoarthritis, uterine fibroids, chronic hepatitis C, viral skin diseases, 
chronic kidney disease due to hypertension, ischemic heart disease (angina, post-MI and heart failure), 
alcohol use disorders, asthma, chronic kidney disease due to glomerulonephritis, injury due to other 
exposure to mechanical forces, and endocrine, metabolic, blood, and immune disorders. Five chronic 
disease and injury states have statistically significant increases in age-standardised rates greater than 5% 
over the period 1990 to 2013: G6PD deficiency, diabetes mellitus, sickle cell trait, other musculoskeletal 
disorders, and urolithiasis. 
Global impairment prevalence 
For five major impairments, Tables 5a-5e shows for each of them the estimated prevalence and the 
distribution of prevalence by cause and severity in 1990 and 2013 (the remaining four impairments are 
reported in Appendix E). Tables 5a-5e also provides overall YLDs due to each impairment to provide 
context on the total burden related to an impairment. 
Table 5a shows that we estimated that 1.83 billion had anaemia in 1990 rising to 1.93 billion individuals 
in 2013. Taking into account the distribution of anaemia across mild, moderate and severe, total anaemia 
YLDs equaled 62.0 million in 1990 dropping slightly to 61.5 million in 2013. This number of YLDs 
makes anaemia from all causes larger than the second leading disease contributing to YLDs, MDD – see 
Table 8b. In addition, to the decrease in overall prevalence, there is a small but notable shift towards more 
cases of mild anaemia and less severe and moderate anaemia over the period. By 2013, just under half 
have mild anaemia, 46.9% have moderate anaemia and 3.9% have severe anaemia. Iron-deficiency 
anaemia accounts for 62.6% of all cases and nearly similar percentages of mild, moderate and severe 
anaemia. The next five most common causes of anaemia overall are thalassemia trait, malaria, gastritis 
and duodenitis, other neglected tropical diseases, and other hemoglobinopathies and hemolytic anaemias. 
Hookworm and schistosomiasis together account for 55.2 million cases and malaria a further 80.6 million 
cases. Over the period from 1990 to 2013, the number of anaemia cases due to malaria increased by 
38.9%. Causes with an increase in cases of more than 50% include chronic kidney disease due to diabetes 
mellitus, chronic kidney disease due to other causes, and sickle cell disorders.  
Table 5b shows that the estimated number of individuals with some form of hearing impairment (20 dB or 
more) rose from 807.2 million in 1990 to 1.23 billion in 2013. Global hearing loss overall accounted for 
25.1 million YLDs in 1990 increasing 51.9% to 36.5 million YLDS in 2013. In 2013, 800.7 million had 
mild hearing loss (less than 35 db) while 414.5 million had moderate or moderate-severe hearing loss. 
The number with complete hearing loss (8.0 million) are somewhat higher than in 1990. Just over 90% of 
hearing loss is classified as age-related and other hearing loss. Otitis media is the next most important 
cause of overall hearing loss but only causes mild or moderate hearing loss. Congenital anomalies 
accounted in 2013 for 2.1% of all hearing loss but 21.1% of complete hearing loss.  
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Table 5c provides a detailed breakdown at the global level of the 61.7 million cases of heart failure (left 
and right-sided) in the world, more than half of which are categorised as severe. The number of 
individuals suffering from heart failure in the world increased 96.4% from 1990 to 2013. One third of 
heart failure is due to ischemic heart disease. Five other causes account for 62.0% of heart failure: 
hypertensive heart disease, other cardiovascular and circulatory diseases, cardiomyopathy and 
myocarditis, COPD, and rheumatic heart disease. All other causes each explain less about 5% of heart 
failure. Notably Chagas disease accounts for 0.6% of heart failure globally but accounts for 11.4% in 
Brazil. All causes of heart failure cause 8.6 million YLDs in 2013.  
Table 5d shows the number of individuals with intellectual impairment increased from 118.2 million in 
1990 to 154.0 million in 2013. In 2013, we estimate that borderline (IQ 70-85) and mild (IQ 50-69) 
accounted for 104.9 million cases and moderate, severe and profound around 49.1 million cases. The 
most important causes of intellectual impairment in order are idiopathic intellectual disability (61.5%) 
followed by neonatal causes (mainly preterm birth complications and neonatal encephalopathy), 
congenital causes (mainly Down’s syndrome and chromosomal unbalanced rearrangements), 
cerebrovascular disease, and infectious causes (mainly meningitis). Comparing levels by cause in 1990 
and 2013, idiopathic intellectual disability increased 22.7%, intellectual disability from preterm birth 
complications 129.6% and intellectual disability from neonatal encephalopathy decreased 5.8%.  
Table 5e examines the distribution of visual impairment including presbyopia in 1990 and 2013. The 
numbers of individuals with visual impairment taking into account the availability of visual aids has 
increased from 518.6 million in 1990 to 774.1 million in 2013. 72.4% of this total in 2013 was 
uncorrected presbyopia. Excluding presbyopia, in 1990 there were 137.0 million with moderate or severe 
vision loss increasing to 178.8 million in 2013. Trends in blindness over the same period were an increase 
from 23.1 million to 33.1 million. The trend in age-standardised rates for visual impairment overall is 
12,702.2 to 11,740.9 per 100,000 and for blindness from 602.5 to 521.3 per 100,000. The most important 
cause of visual impairment in terms of prevalence and YLDs is uncorrected refractive error accounting 
for just over 85% of all cases and 56% of YLDs due to vision impairment. In terms of YLDs, the next 
most important cause is cataract followed by other vision loss, preterm birth complications, glaucoma, 
macular degeneration and diabetes.   
Overall global trends in numbers of YLDs 1990 to 2013 
Figure 3 compares the leading causes of global YLDs in 1990 and 2013, using Level 4 of the GBD cause 
hierarchy which provides detailed cause breakdowns which most relevant to prioritizing specific 
programs or interventions. The top cause in 1990 and 2013 was low back pain. The second leading cause 
has changed due to the decline in iron-deficiency anaemia and the rise in MDD. Two more top ten causes 
are musculoskeletal disorders: neck pain and the large category of other musculoskeletal disorders. Other 
top ten causes include migraine, age-related hearing loss, COPD, anxiety, and diabetes. Causes that have 
increased more than 2 ranks over the period 1990 to 2013 include diabetes mellitus, osteoarthritis, 
dysthymia, medication overuse headache, and Alzheimer's disease and other dementias. Declines of more 
than two ranks have been observed for dermatitis, diarrheal disease, acne vulgaris, conduct disorder, and 
war and legal intervention.  
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Global prevalence and YLDs and age-standardised YLDs 1990 to 2013 for specific 
causes 
Table 6 provide estimates of prevalence and YLDs at the global level for 1990 and 2013 for each cause 
(the full detail at the level of sequelae is available in Appendix Tables F.1 and F.2; Appendix Table F.3 
provides prevalence, YLD, and change by between 1990 and 2013 by cause and age group and Appendix 
Table F.4 provides prevalence, YLD and change between 1990 and 2013 by cause and country). In the 
GBD framework, individuals should be assigned to a unique sequela such that the sum of the YLDs or 
prevalence by sequela should equal the total prevalence and YLDs for a disease or injury. Both because 
specific sequela are of substantive interest in their own right to help target interventions or needs for new 
interventions, and to enhance the transparency of computation, we provide the full list of causes and 
sequelae. Comparison of the percent change in absolute number of YLDs from 1990 to 2013 and the 
percent change in the age-standardised YLD rate highlights where demographic change, both population 
increase and rising mean age, have had a major impact. Age-standardised YLDs and prevalence for a 
number of infectious diseases have statistically significant declines greater than 10% including diarrheal 
diseases, typhoid, paratyphoid, lower respiratory infections, meningitis, encephalitis, diphtheria, 
whooping cough, tetanus, measles, Chagas, African trypanosomiasis, cysticercosis, cystic echinococcosis, 
lymphatic filariasis, onchocerciasis, trachoma, rabies, ascariasis, trichuriasis, and hookworm. In contrast, 
statistically significant increases in age-standardised rates greater than 10% have been observed for HIV 
(from 1990 to 2013, but declines since 2005), cutaneous and mucocutaneous leishmaniasis, and dengue. 
Some other conditions such as malaria, tuberculosis, upper respiratory infections, varicella, visceral 
leishmaniasis, and schistosomiasis have not had significant changes in either direction greater than 10%.  
Age-standardised YLD rates for all maternal causes and sequelae combined are declining significantly.  
Overall age-standardised YLDs for neonatal disorders increased 80.5% from 1990 to 2013. Large 
increases in age-standardised rates have been observed for all neonatal causes. Age-standardised YLDs 
and prevalence of nutritional deficiencies are decreasing as are the absolute numbers of cases. While there 
is a decline in the age-standardised rates for syphilis, for chlamydia and gonorrhea the trends are either 
non-significant or small. Hepatitis B and C are declining significantly but hepatitis A and E have non-
significant trends. Of note, the number of individuals with chronic hepatitis C infection is increasing.  
Age-standardised rates for YLDs from all non-communicable diseases changed by only 1.4% from 1990 
to 2013 but YLD numbers increased by 54.2%. Stagnant overall rates mask highly diverse trends for 
specific causes. Overall neoplasm YLDs are up 82.5% and age-standardised rates increased significantly 
by 8.5%. However, within neoplasms, significant declines have been observed for stomach cancer, liver 
cancer due to alcohol, liver cancer due to other causes, larynx cancer, cervical cancer, nasopharynx 
cancer, gallbladder and biliary tract cancer, and bladder cancer. Significant increases have been seen for 
liver cancer due to hepatitis C, breast cancer, prostate cancer, colon and rectum cancer, pancreatic cancer, 
non-melanoma skin cancer, kidney cancer, thyroid cancer, non-Hodgkin’s lymphoma, and other 
neoplasms. Of note, there is no significant change in the age-standardised trachea, bronchus, and lung 
cancer age-standardised rates. YLDs for cardiovascular diseases overall increased 89.2% but age-
standardised rates did not change significantly. Among cardiovascular causes,   age-standardised YLD 
rates declined significantly for atrial fibrillation and flutter and peripheral vascular diseases. In contrast, 
age-standardised rates increased significantly more than 5% for hypertensive heart disease and 
cardiomyopathy and myocarditis.  
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Numbers of YLDs from chronic respiratory diseases are increasing (55.1%) but rates have remained 
stagnant. Overall cirrhosis age-standardised prevalence and YLD rates are declining although for cirrhosis 
caused by hepatitis C there is no significant change. Among the digestive diseases, gastritis and 
duodenitis, appendicitis, inguinal, femoral and abdominal hernia, gallbladder and biliary diseases, and 
other digestive diseases are increasing in absolute terms but have declining age-standardised rates. In 
contrast, inflammatory bowel diseases, paralytic ileus and intestinal obstruction, and pancreatitis are 
increasing in numbers and rates. As a group YLDs from neurological disorders increased 59.6% but age-
standardised rates increased only 5.0%. There was no significant change in age-standardised rates for 
Alzheimer’s and other dementias but YLD numbers increased 91.8%. A similar pattern was observed for 
Parkinson’s disease and primary epilepsy which are currently thought to be mainly genetic in origin. 
YLDs from multiple sclerosis are increasing in rates and numbers. It is not clear if this increase in rates is 
due to improvements in case ascertainment or reflects a true increase in disease experience. Among the 
headache disorders, only medication overuse headache had a significant change in rates of 43.3%.  
Overall mental and substance use disorders YLDs increased 45.0% from 1990 to 2013 but there was only 
a 1.0% increase in age-standardised rates. Across all conditions in this group, there were not significant 
increases or decreases in age-standardised rates greater than 10% including conditions such as autism, and 
Asperger along with anorexia nervosa and bulimia. Diabetes mellitus YLDs increased by 135.7% but age-
standardised rates increased only 43.4%. In contrast, chronic kidney disease increased 49.5% but rates 
declined 2.8%. Trends in age-standardised rates were different among specific causes of chronic kidney 
disease (CKD) with CKD due to diabetes increasing but CKD due to hypertension and glomerulonephritis 
decreasing. Among urinary diseases, the increase in numbers and age-standardised rates for urolithiasis is 
notable. For most gynecological diseases, numbers are increasing but the significant trend in age-
standardised rates is small; uterine fibroids is an exception with declining rates and only a small increase 
in numbers.  
YLDs for the large category of musculoskeletal disorders are increasing by 60.7% but there was no 
change in age-standardised rates. The only exception to this general pattern is rheumatoid arthritis where 
age-standardised rates declined significantly by 4.6%. As a group, YLDs due to congenital disorder 
increased 61.4% and age-standardised rates by 19.7%. These large increases in numbers and age-
standardised rates have been observed across the board for congenital causes except for Klinefelter 
syndrome where rates have not increased significantly. The reason for this large increase in prevalence 
and YLDs is the improved survival as birth prevalence for congenital disorders remained stable or 
declined. While skin diseases as a group have had no significant trend for age-standardised YLDs, some 
causes have declined significantly including cellulitis, pyoderma, and decubitus ulcer. Most causes of 
vision and hearing loss included in the sense organ category are increasing in absolute number of YLDs 
but have declining age-standardised rates.  
Finally, there is a general pattern where injury YLDs have had substantial decreases in age-standardised 
YLD rates. There are decreases of more than 30% for road injuries, drowning, fire, heat and hot 
substances and poisoning, venomous animal contact, non-venomous animal contact, and self-harm.  
Changes in YLD rates vary by condition, but the changes in rates generally affect the entire age range 
across conditions. However, the main conditions that drive change in YLD rates vary with age. In 
childhood, most infectious diseases and iron-deficiency anemia show decreases in YLD rates while 
neonatal disorders and congenital conditions show increases, largely due to lower initial case fatality and 
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better long term survival, and in the case of preterm birth complications, an increase in the birth 
prevalence. In young adults, large increases from 1990 to 2013 were in disability associated with diabetes, 
HIV, and medication-overuse headache, while there were large decreases in the YLD rates of iron-
deficiency anemia, falls, and collective violence. In adults over the age of 50, reductions in YLD rates for 
all injuries and increase in diabetes YLD rates stand out. 
Leading causes of YLDs for 188 countries 
Figure 4 shows the ten leading causes of YLDs for each country. Causes are colour-coded by their global 
rank to highlight where causes vary substantially in the leading set. There is considerable consistency in 
the top causes. Low back pain and MDD are among the top ten causes of YLDs in every country. Forty 
causes appear in the top ten list across all countries but only 16 of these causes appear in the top ten of 
more than 20 countries. Low back pain is the leading cause in 45 of 50 developed countries and MDD is 
the leading cause in three countries, with neck pain and diabetes leading in one country each. Across 
developing country regions, there is more variation in leading causes. Low back pain or MDD is the 
leading cause in 94 of 138 developing countries. But other conditions such as iron-deficiency anaemia, 
HIV, and war are leading causes in more than one country. Regional patterns emerge such as the more 
prominent role of falls in Central Europe where it is ranked second in 11 of 13 countries. The category 
other musculoskeletal – which includes conditions such as shoulder problems, pathological fractures from 
osteoporosis, osteomyelitis, and pyogenic arthritis, and systemic lupus erythematous – is prominent in 
high-income Asia and high-income North America. Anxiety disorders rank more highly in many 
Caribbean nations and diabetes is prominent in Mexico, Nicaragua, Panama, and Venezuela. In Oceania, 
some soil-based helminths are highly prevalent, pushing them into the top 5 of the YLD rank list. 
Onchocerciasis, predominantly the onchocercal skin sequela, is ranked highly in Liberia, Cameroon, and 
South Sudan. The disability from past war and conflict ranks as the top cause of disability in Cambodia, 
Nicaragua, and Rwanda, and number two in Vietnam.  
Changing YLDs per capita 1990 to 2013 for 188 countries 
Figure 5 provides an analysis of the change in the YLDs per person from 1990 to 2013 by country 
Countries have been ordered by YLDs per person in 1990. YLDs per person in 1990 and 2013 are marked 
by purple and red lines respectively. Across countries in 1990, YLDs per capita range from 0.072 to more 
than double at 0.170. In general, developed countries with higher mean age for the population have higher 
YLDs per capita but there are many exceptions to this general pattern. Change in the YLDs per capita are 
decomposed into contributing causes shown as coloured bars for cause groups for YLDs – for 
convenience these cause groups are based on highlighting the major causes of YLDs at the global level. 
Reductions in YLDs per capita from a cause from 1990 to 2013 are shown as coloured bars to the left of 
the 1990 starting level (purple line) and increases in YLDs per capita from a cause are shown as bars to 
the right of the starting line. The figure provides a summary of what causes are contributing to increases 
or decreases in YLDs per capita for each country.  
The majority of countries (139 of 188) saw increases in the YLDs per capita from the period of 1990 to 
2013. While the drivers of increased YLDs per capita vary by region and country, in general, 
musculoskeletal, mental and substance use disorders, neurological disorders, and chronic respiratory 
conditions play important roles across the majority of regions and countries. In sub-Saharan Africa, 
increases are largely driven by HIV/AIDS. Declining levels of iron-deficiency anaemia contribute to a 
decline in YLDs per capita in many countries. In the subset of countries where the overall YLDs per 
capita declined, specific factors such as long-term disability due to war are an important factor – most 
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dramatically evident in Lebanon. However, declines due to neglected tropical diseases and malaria, as 
well as diarrhea and lower respiratory infections (represented as ‘other communicable’ in Figure 5) also 
push YLDs per capita lower in some countries. Mostly increasing YLDs per capita mean that by 2013 the 
range across countries is from 0.076 to 0.153. It is important to note that Figure 5 shows YLDs per capita 
and not age-standardised YLD rates, therefore changes in YLD rates are influenced by changes in 
population age structure, as well changes in age-specific disease rates.  
YLDs per capita are rising in the majority of countries and YLLs per capita are declining. Both trends are 
leading to a shift towards greater disability as a share of overall burden. Using the results on YLLs 
published by Naghavi et al., we show in Figures 6a and 6b the ratio of YLDs to YLDs plus YLLs (namely 
DALYs).76 The two panels show the progressive shift from 1990 to 2013 in many parts of the world. 
Thirty countries now have a majority of DALYs due to YLDs representing a major change from historical 
patterns where premature mortality was the dominant set of health issues. In 1990, premature mortality 
still represented more than half of DALYs in every country. By 2013, the lowest YLD to DALY ratio 
outside of sub-Saharan Africa was in Afghanistan, but the majority of developing countries outside of 
sub-Saharan Africa have ratios greater than 35%. In sub-Saharan Africa, however, the ratio of YLDs to 
DALYs ranges from 10.4% in Mali to 38.9% in Cape Verde.  
Discussion 
We analysed over 30,800 epidemiological sources from 188 countries spanning the last three decades to 
provide the most up-to-date empirical assessment of the leading causes of acute disease incidence, 
chronic disease prevalence, and YLDs for six years (1990, 1995, 2000, 2005, 2010, and 2013) for 188 
countries using consistent and comparable methods. More importantly, our study provides the first ever 
comprehensive assessment of the extent, pattern and trend of non-fatal health loss in countries, with 
attendant implications not only for health policy, but also for the provision and financing of health 
services.  
A wide array of disease and injury sequelae affects the world’s population. Disease is ubiquitous and we 
find that globally in 2013 only 4.3% of the population has no GBD disease or injury sequelae up slightly 
from 4.2% in 1990. There are 59 diseases and injuries with a global prevalence of greater than 1% but 
each of which causes comparatively little disability. These conditions including various causes of mild to 
moderate vision impairment, hearing loss, soil transmitted helminths, mild anaemia, caries, and many 
others. For many of these common but relatively mild conditions, there are effective interventions.87–90 
The GBD provides multiple insights into the health experience of different populations by quantifying the 
prevalence of a wide variety of conditions as well as YLDs that take into account the general public’s 
view of severity.  
Of the 240 GBD causes that lead to mortality, Naghavi et al. found that global age-standardised death 
rates were declining in 80%.76 For YLDs, the distribution of causes where age-standardised rates are 
declining, stagnant or increasing is different. For 140 causes, distributed across communicable, non-
communicable, and injuries, age-standardised rates have declined significantly from 1990 to 2013. For 89 
causes, changes in age-standardised rates are statistically indistinguishable from zero over the same 
period. For 72 causes including epidemic conditions like HIV and dengue but also cancers, diabetes, and 
COPD age-standardised rates increased significantly. Of 301 causes, the percent change in the age-
standardised rate for YLDs is higher than the percent change in the age-standardised YLLs for 213 
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causes. Divergent rates for diseases and injuries between mortality and morbidity could be occurring 
because of reductions in case-fatality rates due to treatment or improved background risks such as 
malnutrition. To the extent that mortality is declining faster than disease prevalence due to treatment, 
access to care may be a critical driver of trends in health. The mortality-disability temporal disconnect, 
however, is further evidence of the importance of paying attention to trends in disease incidence, 
prevalence and YLDs and not simply focusing on mortality. Diabetes is an important example where age-
standardised prevalence rates increased 43% while death rates increased only 9%. Stagnant or increasing 
age-standardised rates combined with rising mean age of the world’s population implies substantial future 
increases in burden from these causes. The documented shift in many developed and developing countries 
to a larger fraction of DALYs coming from YLDs is another manifestation of this global shift. Despite the 
evidence on this shift, the majority of global health policy discussion remains focused on premature 
mortality. For example, in the Sustainable Development Goals Open Working Group proposal91 with 13 
targets for the health goal, only one on narcotic drug abuse and harmful use of alcohol is focused on a 
disability.  
While the general pattern of the last 23 years has been for infectious disease mortality and morbidity 
measured through incidence or prevalence to decline, there are some very notable exceptions that stress 
that such trends are not inevitable with rising income per capita and educational attainment. Comparing 
1990 and 2013, both HIV and malaria YLDs increased. More careful examination of our estimates for the 
six time periods shows that malaria and HIV YLDs have been declining since at least 2005. Increases for 
dengue (nearly 450%), for cutaneous and mucocutaneous leishmaniasis have continued through the 
period. Increases in dengue have been ascribed to the rise of breeding sites for the mosquito vector in 
urban and peri-urban areas.92 Increases for cutaneous leishmaniasis have been related to the expansion of 
previously non-endemic areas as a result of urbanisation and deforestation with domestic animals as 
potential reservoirs. Additionally, economic hardship, natural disasters, armed conflict, movement of 
seasonal workers, development of new projects, and bringing non-immune labor forces into endemic 
areas are contributing causes. Finally, pressure on populations throughout the world are pushing 
migration into areas where the infection is endemic, thereby bringing many more humans into contact 
with the natural vectors and resulting in increased infection rates.93–96 These counter trends for infectious 
diseases are a reminder that active surveillance of infectious diseases at a fine-grained geospatial level is 
essential to detect changes that may run against the general trend towards lower rates.  
The GBD 2010 reported that the burden of musculoskeletal disorders were much larger than previously 
appreciated.7,8,19,20,37,38 In this analysis, we demonstrate that musculoskeletal disorders range from 9.6% of 
YLDs to 28.9% of YLDs between 188 countries. Low back pain is the leading cause of YLDs in 86 
countries and the second or third leading cause in 67 countries. While the GBD 2010 analysis brought 
more attention to these disorders, there remains comparatively little policy discussion of the options 
available to address and prevent these conditions.1,97 From a health service point of view, it is important to 
note that there is a connection between the injury analysis of fractures and soft tissue injury and 
musculoskeletal disorders. We estimate 22 million YLDs from fractures, the vast majority of which is 
long-term disability. Most of the individuals afflicted would present with a musculoskeletal chief 
complaint in surveys and therefore to avoid double counting we subtracted the long-term disability from 
fractures and dislocations out of the estimates of the category of other musculoskeletal conditions. 
Musculoskeletal disorders combined with fractures and soft tissue injuries reaches a total of 20.8% of 
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global YLDs in 2013; across countries this total ranges from 10.8% in Mali to 30.0% in South Korea. Our 
analysis of time trends clearly shows this category of conditions is an important driver of rising YLD 
rates per capita. Increases are driven by aging of the population in most countries with trends in obesity 
and physical inactivity likely exacerbating the problem.98,99 Musculoskeletal disorders are not only an 
important contributor to the burden of disease but are also a critical component of health expenditure in 
many high-and middle- income countries.100–104  
Mental and substance abuse disorders account for 21.2% of YLDs, ranging from 15.4% in Germany to 
36.7% in Qatar. MDD is a critical contributor in developed and developing countries alike: it is the 
leading cause of YLDs in 56 countries, the second leading cause in 56 countries, and the third in 34 
countries. While MDD, anxiety disorders, schizophrenia and bipolar disorder are leading causes in nearly 
all countries, there is much greater country variation in substance use disorders including alcohol. YLDs 
from alcohol use disorders range from a high of 2.9% in Russia to a low of 0.3% in Iran; YLDs from drug 
use disorders range from a high of 13.5% in Qatar to a low of 0.6% in Slovenia. New data in the GBD 
2013 suggests that Iran and Afghanistan have particular problems with opioid dependence. The GBD 
2013 analysis confirms that common mental disorders have well-established sex patterns in most 
countries: higher rates in women for MDD and anxiety and similar rates for bipolar and schizophrenia for 
men and women. Treatments if widely and appropriately deployed could lead to substantial reductions in 
the burden of these disorders; some studies suggest that up to half of YLDs could be averted in some 
countries.1,105,106 As new studies accumulate on the role of childhood sexual abuse, intimate partner 
violence, non-sexual child abuse and bullying, the possibility of prevention programs is growing.107–111 
Systematic quantification of these risks will help establish where prevention programs could be developed 
and tested.  
Advances and gaps in GBD data and methods 
For the first time in the GBD studies, we provide a systematic quantification of the geographical and 
temporal coverage of the input epidemiological data for nearly all sequelae. For a number of diseases with 
sequelae representing different levels of severity such as MDD (mild, moderate, and severe sequelae), the 
data representativeness metrics show there are often more data for overall disease prevalence than for 
determining the distribution of severity for a cause. Sequelae with the highest data representativeness 
index (DRI) tend to be those where administrative data such as notifiable disease reporting or hospital 
discharge data can be corrected for completeness and/or selection bias. For some sequelae, such as drug 
use disorders a single study was available to determine the distribution of cases by level of severity. 
Despite attempts to quantify uncertainty from various sources in the estimates (see limitations below), it 
is highly likely that for sequelae with low DRIs uncertainty may be larger than estimated. At the global 
level, twelve of the top causes of YLDs have a DRI less than 0.25. Priorities for further data collection in 
a country might usefully be informed by comparing the estimated YLDs and the DRI for the country for 
each cause. Examining countries, the fraction of sequelae with any data available in a country, shows 
marked variation across countries within a region or within income group – consider Nigeria with a DRI 
of 47% and Mauritania at 10% or the United Kingdom at 81%and Greece at 52%. Our computation of the 
DRI is based on the data available to the GBD through published studies or reports, publicly released 
datasets, and unpublished data provided. Given our experience in China and Mexico with sub-national 
burden of disease estimation, it is likely data coverage could be improved through detailed national 
burden of disease studies which often unearth multiple unpublished sources. Ministries of Health and 
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national statistical authorities in countries with low coverage should carefully assess which high burden 
conditions with low data availability would benefit from new data collection efforts.  
With each iteration of the GBD, the cause and sequelae list have expanded. Expansion involves taking an 
existing cause and splitting it into more detailed component causes; for example, eating disorders were 
broken down into anorexia nervosa and bulimia. Within each Level 2 or Level 3 cause group, there is a 
category of other such as other mental, musculoskeletal, or neurological disorders. These residual 
categories contain many rarer causes and some common causes that have very low levels of disability. 
One of the key values of the GBD is the comprehensive and systematic nature of the analysis; it is likely 
that in future iterations based on health service utilisation data or new epidemiological studies or policy 
demand, the cause and sequelae list will be further expanded. The GBD cause list, even in the current 
expanded form, still has only 301 causes compared to the 11,299 four-digit ICD-10 codes. The GBD 
cause list provides a more manageable public health and health service planning focused approach to the 
complexity of disease coding. The sequela list also has many potential applications, such as facilitating 
the mapping of data collected through different studies and typologies into a common framework.  
For GBD 2013, the study has benefited from use of a larger computational cluster compared to GBD 2010 
(22 teraflops compared to 8 teraflops). The optimised recoding of DisMod-MR 1.0 to DisMod-MR 2.0, 
combined with greater computational capacity, has allowed us to generate country-specific posterior 
estimates for incidence, prevalence, remission, and excess mortality for each of six time periods. We have 
estimated and reported internal validity of different models and conducted cross-validation studies for 10 
of the models. We believe DisMod-MR 2.0 is a substantial improvement over DisMod-MR 1.0 but there 
remains considerable opportunity to improve these data synthesis tools in the future. In particular, work is 
underway to develop the next iteration of DisMod-MR that would allow for variation of incidence, 
remission, excess mortality rates simultaneously over age, geography, and time in contrast to the present 
approach, where variation in rates over time is captured by independent estimation of the available data 
for six different time periods. Despite progress in the estimation tools, a fundamental problem in 
epidemiological synthesis of sparse and heterogeneous data is distinguishing between true variation in the 
underlying rates and study heterogeneity due to variation in case definitions, assays, instruments, 
sampling frames etc. DisMod-MR 2.0 allows explicit modeling of these factors but true resolution of this 
challenge requires more data to be collected with consistent definitions and study design.  
The comorbidity micro-simulation for each country-age-sex-year has been used to quantify both co-
morbidity and allocate to contributing causes the individual’s disability weight. By weighting up each 
country-age-sex-year micro-simulation by the true population in each age-group, we have created a 
working model of individual health for all 7.3 billion individuals in the world consistent with the entire 
GBD non-fatal health outcome results. With future iterations of the GBD, we intend to incorporate data 
on risk factors into the global micro-simulation providing an even more comprehensive working model of 
each country’s population. This global and national micro-simulation has many potential applications 
from inequality measurement to comprehensive forecasting of multiple interventions. For example, the 
GBD micro-simulations provide an ideal environment for modeling the impact of interventions that 
would reflect the complex interplay between conditions that is often missing in many intervention impact 
assessments. The distribution of functional health status across individuals in each country for different 
points in time can also be used to compute measures of individual inequality in functional health. If the 
correlations between socio-economic indicators within each country-age-sex-year group with health 
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outcomes and risk factors can be estimated, then the micro-simulation environment could also be used to 
look at the relationship between health and income inequality.  
Disability weights through the inclusion of new data from national surveys in Italy, Hungary, Sweden and 
the Netherlands and revisions in lay descriptions for selected health states have changed from those used 
in the GBD 2010. The severe hearing loss disability weight increased from 0.05 to 0.18 with similar 
increases for profound hearing loss and deafness. Through the inclusion of incontinence in the lay 
descriptions for spinal cord lesion below the neck, the disability weight increased from 0.047 to 0.296. 
These findings highlight the critical importance of the exact wording of lay descriptions for use in 
population surveys. We revised lay descriptions in the latest round of data collection based on critical 
commentary in the literature and a careful review of all lay descriptions checking for symmetry and 
consistency. We believe that future iterations of the GBD will benefit from further data collection and 
vigorous scrutiny and debate by the scientific community of the exact lay descriptions in use – see 
Appendix Table A.6 for a full listing and Salomon et al. for further detail.84  In many countries 
undertaking sub-national burden of disease studies, there may be opportunities to collect further disability 
weight data using the latest iteration of the GBD lay descriptions and measurement protocol. Such data 
would help establish if there is any notable national variation in disability weights from the global average 
and strengthen the global empirical database for disability weight measurement.  
The second important component determining average disability weight is the empirical analysis of the 
distribution of severity controlling for comorbidity. The number of studies or data sources that allow for 
teasing apart functional health limitations from a particular cause from other comorbid causes remain very 
limited. Very low DRIs for many sequelae in Table 1 document this limitation. More datasets like the US 
Medical Expenditure Panel Survey that include both functional health limitation measurement and ICD-
coded diagnoses would be extremely helpful in strengthening the empirical assessment of severity 
controlling for comorbidity. This must be considered one of the most important data gaps for the 
quantification of many chronic conditions.  
GBD 2013 compared to GBD 2010 and other estimates 
Because the GBD 2013 has re-estimated prevalence and YLDs for all disease and injury sequelae for 
1990, 1995, 2000, 2005, 2010, and 2013, we can compare the results of the GBD 2013 directly with the 
GBD 2010. The leading global causes of YLDs estimated for the year 2010 in this study (low back pain, 
MDD, iron-deficiency anaemia, neck pain, and age-related and other hearing loss) are similar to those 
reported in the GBD 2010 (low back pain, MDD, iron-deficiency anaemia, neck pain, and COPD) for the 
year 2010. For 97 diseases or injuries, global YLDs from the GBD 2013 for the year 2010 are statistically 
different from the GBD 2010 estimates for the same year. For 27 diseases and injuries, there were 
changes in YLDs greater than 30% but these changes were not statistically different than GBD 2010. In 
general, changes stem from the inclusion of new data, exclusion of studies used in GBD 2010 due to 
changes of inclusion criteria for each sequela that emerged through the process of replicating many GBD 
2010 systematic reviews, the shift to DisMod-MR 2.0 which reduced the impact of large sample size 
outlier studies, changes in covariates, changes in disability weights, or changes in severity distributions. 
Appendix Table A.8 provides a more detailed account for each of these cases including changes in 
inclusion criteria where relevant. At the level of global YLDs, the most notable impact of these changes is 
the inclusion of age-related and other hearing loss in the top 10 causes of global YLDs; this change is 
almost exclusively due to the revision of the hearing loss disability weights. The annual updating cycle 
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for the GBD provides a much more rapid cycle for incorporating new data and critical scientific feedback 
from GBD collaborators and the broader scientific community. We expect that with each iteration there 
will be important changes driven by the collection and release of new data but that the number of changes 
driven by uncovering older studies, exclusion of older studies on quality grounds, or changes in modeling 
strategy will tend to get smaller with each iteration.  
Limitations 
A study of this scope has multiple limitations many of which were detailed in the GBD 2010 analysis.1 
Here we focus on selected major limitations that are not specific to the data sources or analysis of a 
specific sequela. First, For COMO to work effectively, especially with the assumption of independence, 
individuals with a disease need to be uniquely mapped to a single sequela. For some diseases where there 
are multiple distinct functional impairments such as motor and cognitive dysfunction for some neonatal 
disorders, multiple combinations are possible. In some cases, to map all of the possible combinations was 
infeasible because of increased computational load and the lack of epidemiological data to accurately 
describe these combinations. In a very limited number of cases, we have not followed the principle of 
mapping one individual to a unique sequela including schistosomiasis, lymphatic filariasis, and 
onchocerciasis.  
Second, a major limitation that may affect many sequelae is that important unpublished data sources may 
be missing. The collaborations with investigators in Mexico, China, and England to generate sub-national 
burden of disease estimates for 2013 has identified multiple unpublished data sources or more detailed 
age and time breakdowns for published studies. It is highly likely that in other countries there are similar 
data sources that once identified, could enrich the estimation of the burden of disease for a country.  
Third, in this analysis of prevalence and YLDs, we attempt to capture uncertainty from model estimation 
and available data but 95% UIs may be too narrow because we cannot capture uncertainty that stems from 
the possibility that countries with data may in some way be different for a given sequela than countries 
with data. Further, in contrast to the GBD analysis of causes of death, we do not capture uncertainty that 
stems from model specification. We have undertaken cross-validation studies for a limited number of 
models but the move to using out of sample validity testing to then create ensembles of good models will 
require further advances in computational speed of DisMod-MR to make this viable.76  
Fourth, for the GBD 2013 we have made a substantial effort involving many person-years of effort to 
enhance the transparency in all aspects of the estimation. In GBD 2010, in some cases contributors who 
undertook systematic reviews provided results but without study references. For GBD 2013, we have 
included in the Global Health Data Exchange (GHDx, ghdx.healthdata.org/) 23,653 citations with 
metadata covering essentially all sources used in any aspect of this analysis. We have provided more 
detail on modeling strategies and internal validity of model fits. Given the complexity of the GBD 
analysis spanning so many sequelae, estimation requires a tremendous investment across the network of 
collaborators measured in person-years. Replication of the entire effort is possible but would require 
considerable resources and negotiated access to the small number of datasets provided to the GBD 
through Data Use Agreements that are not in the public domain. With the public release of the Epi Viz 
tool, everyone will be able to examine the specific studies and data points used for each disease sequela 
and the model fits. To further satisfy the reasonable scientific curiosity of academics about particular 
sequelae, the GBD collaborators remain committed to answering detailed questions about all steps of the 
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analysis and many disease-specific publications will follow in which much greater detail of the modelling 
assumptions and data for each sequela can be provided.  
Fifth, where data for a sequela are collected using different definitions, assays, or instrument items, we 
have ‘cross-walked’ between these differences using fixed effects in the meta-regressions. For example, 
in the DisMod-MR 2.0 model for MDD, the coefficient on symptom scale measures as opposed to a 
diagnostic interview schedule is 0.83 (0.64-1.04) in log space and 2.30 (1.90-2.83) after exponentiation. 
By dividing symptom scale prevalence data points by 2.3, we predict the corresponding values for the 
reference case. Another example of an important cross-walk is between data on opioid dependence from 
household surveys and the more inclusive estimates from triangulation of data from treatment centres, 
needle exchange programs and the justice system.9 DisMoD-MR 2.0 estimates a coefficient of 0.31 (0.15 
to 0.74) after exponentiation indicating the household survey prevalence is an underestimate by more than 
a factor of three. A number of factors could explain this large difference including lack of a steady 
residence, lower response to surveys and fear of reprisals for admitting to illegal behaviors.112 We used a 
similar covariate for triangulated data on cocaine and amphetamine dependence but found no systematic 
bias compared to household survey data. There is no equivalent approach to address the potential bias 
from non-response to surveys or the influence of stigma on responses for cannabis and alcohol 
dependence. In the DisMoD-MR 2.0 model of alcohol dependence we use a number of study 
characteristics such as the type of survey and the measurement instrument. A review of Chinese studies 
on alcohol dependence found that variation in prevalence between studies was strongly correlated with 
such study characteristics.113 Of particular interest in the Chinese review is their finding that large surveys 
often rely on proxy reporting for absent household members to improve the response rate and that these 
surveys tend to underestimate the prevalence of alcohol dependence. While there is a considerable body 
of evidence describing stigma and alcohol dependence there is no quantification of the magnitude and 
direction of the bias on population prevalence estimates, probably because  it is hard to define a gold 
standard measurement that would be unaffected by stigma.114–116 Experience in the GBD 2013 compared 
to GBD 2010 shows that these fixed effect coefficients for study level characteristics can be substantially 
influenced by the inclusion of new data sources. Where cross-walks are large, new data in one country 
can alter results in many other countries. This sensitivity of statistical cross-walks in models with sparse 
data highlights the value of standardising case definitions, assays and instruments in future data 
collection. The comprehensive nature of the GBD provides an opportunity to identify what is the 
reference case approach to measurement given current knowledge for each sequela. We plan to 
summarise our assessment of best practice for each sequela in a future publication.  
Sixth, in models using DisMod-MR 2.0 or natural history models, the relationships between incidence, 
remission, excess mortality, prevalence, and cause-specific mortality are modeled simultaneously. 
However, if there are no priors on the age pattern and level of excess mortality across countries, 
simultaneous estimation does not ensure any correlation in the age-specific rates of prevalence and cause-
specific mortality across countries. In this iteration of the GBD, we have devoted much more attention to 
this estimation challenge by incorporating in many models more direct information on the credible range 
of excess mortality across age, sex, and country. However, country variation in excess mortality has not 
been as extensively debated in the literature on burden of disease estimation as for incidence, prevalence, 
or causes of death. More attention to these relationships and the determinants of excess mortality such as 
access to care will be beneficial in future iterations of the GBD.  
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Seventh, COMO, used for quantifying the burden of disease and undertaking intervention analysis, 
suffers from a major limitation, namely that we assume that within a country-age-sex-year group that 
prevalence values are independent. For some conditions such as diabetes and ischemic heart disease or 
anxiety disorders, depression and alcohol dependence, we expect probabilities are dependent. Empirical 
assessments 117,118 of comorbidity tend to show that age is the dominant driver of comorbidity – ignoring 
dependent comorbidity, for example in the MEPS data, leads to minimal errors in estimated burden.1 
Incorporating dependent comorbidity into the micro-simulation environment is not technically 
challenging; the issue is that there are insufficient data to generally estimate the age-specific correlation 
matrix of all 2,337 sequelae. As compelling and albeit partial evidence on dependence accumulates, we 
intend to incorporate this into the COMO micro-simulations.  
Eighth, in the current version of DisMod-MR 2.0 we were unable to incorporate estimates of the sub-
national units for China, Mexico, and the UK as a fifth level in the estimation cascade (Figure 2). Instead, 
subnational units were modeled as if they were independent countries. If data are sparse, it means that 
subnational units may borrow strength from the regional estimate rather than the country estimate. In 
some cases, where only national data were available, we used this data for each sub-national unit after 
dividing the effective sample size of each data point by the number of sub-national units to avoid over-
emphasising the national data used in each unit in the overall estimation. A fifth level of the cascade will 
be added in the next version of DisMod-MR.  
Ninth, there has been a steady drop in the age-standardised rates of YLDs for all injury categories 
between 1990 and 2013. For the unintentional injury categories apart from falls this is partly driven by a 
downward trend in case fatality rates accompanied by a drop in incident cases. The larger change 
affecting the downward trend in YLD rates is related to the difference between disability with and without 
treatment. In the absence of robust national data on the injury treatment rates, we have assumed that 
access to treatment scales according to the indicator health system access.76 The health system access 
indicator is based on a principal component analysis of coverage of mostly maternal and child health 
interventions and health system infrastructure. There have been steady global improvements in health 
system access as captured in this indicator reducing the estimated injury YLDs.  
Tenth, substantial efforts have been made in the data preparation and analysis to address issues of 
ascertainment bias that may affect trends. In another example of dealing with ascertainment bias we 
cross-walk between diagnostic assays from CK-MB enzymes to troponins for the detection of acute 
myocardial infarction. Despite these efforts, there are some upward trends that may still relate to residual 
issues of ascertainment including multiple sclerosis and prostate cancer. 
Eleventh, in a study with over half a million YLD estimates generated from sometime sparse and always 
disparate data sources there remain areas where additional evidence or a change in the modelling strategy 
could lead to better estimates. Annual updates of GBD allows for a continuing effort to search for new 
data and improve methods, particularly for conditions with sparse data or inconsistencies between data 
sources.We are already compiling a list of issues to address in the next iteration.  For example, with our 
collaborators in Qatar, we are searching for data to verify the high YLD estimate for opioid dependence 
which currently are influenced in the models by studies in in Iran and Afghanistan in the region. In other 
cases, further data on the clinical severity associated with paragonimiasis would help determine the 
relevance of the health state used to select the disability weight for this sequelae. In general, we will 
search for additional evidence on the severity of all conditions for the next iteration of GBD. 
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Conclusions 
Despite these limitations, the implications of our findings are substantial. By extending the GBD analysis 
to report on commonly understood measures of morbidity and disability in populations, by age, by sex, by 
country and over time, this study represents an enormous resource for national, regional, and global 
policy debates about health priorities , not just to keep people alive well into old age, but to also keep 
them healthy. Without this health intelligence, large, preventable causes of health loss in populations, 
particularly mental and behavioral disorders and serious musculoskeletal conditions, have hitherto not 
received the attention that they deserve in national health debates.  
The GBD 2013 covers a comprehensive collectively exhaustive and mutually exclusive set of causes and 
their sequelae at the country level over a period of 23 years. By shifting to a process of annual updating, 
the GBD provides a relatively rapid mechanism for incorporating new data, methods development, and 
new insights into old data or disease mechanisms. By steadily increasing the transparency of input 
sources, documenting in detail the methods used, sharing critical code such as DisMod-MR 2.0, and 
facilitating on-line exploration of new results using dynamic data visualisations (www.healthdata.org), we 
believe the GBD can progressively become the vehicle for global health surveillance, not just for 
mortality, but for reducing health loss among populations everywhere. As a group of investigators, we 
seek to accommodate within the GBD framework epidemiological debate on each cause, and based on 
scientific principles, describe the functional health of all individuals in the world. Studies such as this 
provide the important comprehensive, comparative, and consistent evidence to guide policy and practice, 
evidence that will become progressively more reliable as more data and information are identified and 
included as part of the global collaboration. 
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Table and Figures 
Table 1. GBD 2013 data representativeness index by cause (causes aggregated in bold), calculated as 
fraction of countries with data for each cause and time period 
Table 2. GBD 2013 data representativeness index by impairment, calculated as fraction of countries with 
data for each impairment and time period 
Table 3. Global incidence of acute sequelae (duration less than 3 months) by cause where incidence is 
greater than 1 million cases per year (causes are ordered in terms of overall incidence, 95% uncertainty 
intervals are shown, statistically significant % change is shown in bold) 
Table 4. Global prevalence of chronic sequelae (duration greater than 3 months) by cause where 
prevalence is greater than 1% (causes are ordered in terms of overall prevalence, 95% uncertainty 
intervals are shown, statistically significant % change is shown in bold) 
Table 5a-5e. Prevalence and YLDs, with percent of total, for 5 impairments (anemia, hearing loss, vision 
loss, intellectual disability and heart failure) by cause, 1990 and 2013, and prevalence by severity in 2013 
Table 6. Prevalent cases and YLDs for 2013, percent change, and percent change of age-standardised 
rates between 1990 and 2013 for all causes (statistically significant % change shown in bold) 
Figure 1. Percent of causes with data available between 1990 and 2013 for 188 countries 
Figure 2a. Population pyramid for developed countries with individuals grouped by number of sequelae, 
1990 and 2013 
Figure 2b. Population pyramid for developing countries (excluding sub-Saharan Africa) with individuals 
grouped by number of sequelae, 1990 and 2013 
Figure 2c. Population pyramid for sub-Saharan African countries with individuals grouped by number of 
sequelae, 1990 and 2013 
Figure 3. Comparison of the rank order of the 25 leading Level 4 causes of YLDs in 1990 to their rank in 
2013. DALYs 
Figure 4. Ten leading causes of YLDs for 188 countries in 2013 (causes are colour-coded by global rank) 
Figure 5. Change in the YLD rate from 1990 to 2013 for 21 regions 188 countries (changes have been 
decomposed into 21 major cause groups and countries are ordered by the YLD rate in 1990) 
Figure 6a. Percentage of DALYs due to YLDs in 1990 for 188 countries 
Figure 6b. Percentage of due to YLDs in 2013 for 188 countries 
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